Claims for Patent: 7,666,652

Summary for Patent: 7,666,652

Title:	Asparaginases
Abstract:	The invention relates to new asparaginases having improved properties, preferably improved thermotolerance, such as improved activity at high temperatures and/or improved thermostability. The invention also relates to DNA sequences encoding such improved asparaginases, their production in a recombinant host cell, as well as methods of using the asparaginases, in particular for reduction of acrylamide in foods. The invention furthermore relates to methods of generating and preparing asparaginase variants having improved properties.
Inventor(s):	Matsui; Tomoko (Chiba, JP), Friis; Esben Peter (Herlev, DK), Yamagishi; Akihiko (Tokyo, JP)
Assignee:	Novozymes A/S (Bagsvaerd, DK)
Application Number:	12/044,055
Patent Claims:	1. A polypeptide which: (a) has asparaginase activity; (b) has at least 90% identity to amino acids 80 to 378 of SEQ ID NO: 1; and (c) comprises an amino acid difference compared to SEQ ID NO: 1 at a position corresponding to position 70 in SEQ ID NO: 1. 2. The polypeptide of claim 1, wherein the amino acid difference is a substitution. 3. The polypeptide of claim 2, which further comprises a substitution in 1- 10 of the following positions: 54, 57, 68, 69, 71-74, 82-86, 88, 93-96, 102, 107, 111, 113, 115, 137, 139, 164, 165, 172, 176, 184-186, 194, 196, 201, 206, 209, 212, 214, 215, 219, 220, 223, 224, 226, 228, 231, 235, 246, 249, 255, 260, 262, 264, 266, 271, 275, 278-288, 290, 299, 306, 307, 309-321, 323, 325, 327-342, 349, 351, 353, 356-363, 365, 366 and/or 375. 4. The polypeptide of claim 2, which further comprises a substitution in 1-10 of the following positions: 54, 57, 83, 84, 86, 102, 137, 164, 196, 201, 228, 260, 262, 278, 283, 290, 307, 312, 323, 327, 334, 336, 337, 349, 351, 353, 366 and/or 375. 5. The polypeptide of claim 2, which further comprises a substitution in at least one of the following positions: 323, 327, 349, 351 and/or 353. 6. The polypeptide of claim 2, which further comprises a substitution in at least position 323. 7. The polypeptide of claim 2, which further comprises a substitution in at least position 327. 8. The polypeptide of claim 2, which further comprises a substitution in at least position 349. 9. The polypeptide of claim 2, which further comprises a substitution in at least position 351. 10. The polypeptide of claim 2, which further comprises a substitution in at least position 353. 11. The polypeptide of claim 2, which comprises 1-10 of the following substitutions: 54I, 57L, 69K/R, 70H/K/P/R/S, 72K/R, 82P, 83P/V, 84P/D, 85P, 86P, 88N, 93L, 94K, 95D, 96L, 102D, 107I, 111N, 113P, 115P, 137P/S/I, 139I, 164D/P, 165L, 172A, 176C, 184Y, 185N, 186A, 194E, 196E/I, 201P/Q, 206N, 209G, 212R, 214V, 215T, 219T, 220T, 223C/L/N, 224A, 228V, 231C, 235Q, 246C, 249I/L/V, 255Q, 260K, 262D, 264L, 266L/K, 271C, 275N, 278H/K/P/Q/R, 279N/R/V, 280D/E/P, 281D/E, 283C, 286L/N/R/V, 290E/L/V, 299N, 306P, 307A/D/E, 311K/Q/R, 312N/R/V/Y, 317D/E, 318G, 320V, 321V, 323R, 325S, 327V, 328C, 331Q, 334F, 336C/G/L/P, 337F/I/K/Q/R, 349Q, 351A, 353I, 356M, 361K/R, 363E/L/P/Q, 365P, 366P and/or 375T. 12. The polypeptide of claim 11, which comprises 1-10 of the following substitutions: 54I, 57L, 70H/K/S, 83V, 84D, 86P, 102D, 137S, 164D, 196I, 201Q, 228V, 260K, 262D, 278H/Q, 283C, 290V, 307A, 312Y, 323R, 327V, 334F, 336C/G/L, 337F/I, 349Q, 351A, 353I, 366P and/or 375T. 13. The polypeptide of claim 12, which comprises one of the following substitutions: N70H, N70K or N70S. 14. The polypeptide of claim 13, which comprises the substitution N70K. 15. The polypeptide of claim 14, which further comprises at least one of the following substitutions: 323R, 327V, 349Q, 351A and/or 3531. 16. The polypeptide of claim 14, which further comprises the substitution 323R. 17. The polypeptide of claim 16, which further comprises the substitution 327V. 18. The polypeptide of claim 16, which further comprises the substitution 349Q. 19. The polypeptide of claim 16, which further comprises the substitution 351 A. 20. The polypeptide of claim 16, which further comprises the substitution 3531. 21. An isolated nucleic acid sequence comprising a nucleic acid sequence which encodes the polypeptide of claim 1. 22. A nucleic acid construct comprising a nucleic acid sequence of claim 21 operably linked to one or more control sequences that direct the production of the polypeptide in a suitable expression host. 23. A recombinant expression vector comprising the nucleic acid construct of claim 22. 24. A recombinant host cell comprising the nucleic acid construct of claim 22. 25. A method for producing a polypeptide having asparaginase activity, the method comprising: (a) cultivating the host cell of claim 24 to produce a supernatant comprising the polypeptide; and (b) recovering the polypeptide. 26. A method for producing a food product, comprising: (a) providing a food material; and (b) treating the food material with the polypeptide of claim 1. 27. The method of claim 26, wherein the food material is heated after step (b). 28. The method of claim 26, wherein the method is for reduction of acrylamide in the food product. 29. The method of claim 26, wherein the food product is a cereal based product; a vegetable based product; or a coffee based product. 30. The method of claim 26, wherein the food product is bread, pastry, cake, pretzels, bagels, cookies, gingerbread, gingercake, breakfast cereals, crispbread, a potato based product, french fries, potato chips, crisps, fabricated potato snacks or croquettes.

Details for Patent 7,666,652

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Recordati Rare Diseases, Inc.	ELSPAR	asparaginase	For Injection	101063	01/10/1978		2027-03-09